Adherium Ltd. (ASK:ADR) said today that it launched a next-gen version of its SmartTurbo adherence monitor for AstraZeneca‘s (NYSE:AZN) Turbuhaler.
The company’s monitor features usability improvements to make the device’s installation and removal easier for older patients with COPD. It also includes larger buttons to help patients access features like audio and visual reminders, battery monitoring and Bluetooth pairing.
Adherium added new sensors to the device as well, the company touted, in the hopes of generating more data to monitor and provide feedback to users.
“We believe that SmartTurbo Model 4 will address a key unmet need for patients with asthma or chronic obstructive pulmonary disease by monitoring and improving adherence to their medications,” CEO Arik Anderson said in prepared remarks. “We are now demonstrating the ability to design, obtain regulatory approvals, transfer to production, and release to market, on an annual cycle – improving the device with each successive generation.”
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
